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TOXIC CHARACTERISTICS OF FLUOROCITRATE, THE TOXIC METABOLITE 
OF COMPOUND 1080 
PETER J. SAVARIE,  Denver Wildlife Research Center, U.S. Fish and Wildlife Service, Building 16, Federal 
Center, Denver, Colorado 80225 
ABSTRACT:  This paper reviews toxicological research involving fluorocitrate, the toxic metabolite of 
sodium monofluoroacetate (fluoroacetate), which is the active ingredient in the pesticide Compound 1080. 
Many toxicological studies have been done with fluoroacetate and the results obtained are actually due 
to the fluorocitrate because it has been definitely proved that, from a biochemical perspective,fluoro-
acetate is not toxic but fluorocitrate is. The classical explanation of the toxic action of fluoroci-
trate is that it inhibits the enzyme aconitase in the tricarboxylic acid cycle. Deactivation of 
aconitase results in decreased energy production by cells and ultimately death of the organism.  
However, the more recent explanation of fluorocitrate's mode of action is that it binds with mito-
chondrial protein which prevents transport of citrate and its utilization by cells for energy production. 
Metabolism studies indicate that only small amounts, perhaps less than 3%, of fluorocitrate is formed 
from fluoroacetate. From the limited number of acute and chronic studies conducted with fluorocitrate 
it does not appear to be as potent as fluoroacetate by either the oral or parenteral routes of admini-
stration. This decreased level of toxicity is thought to be due to the larger molecular weight of 
fluorocitrate which would not be as readily absorbed by tissues. Central nervous system toxic mani-
festations (i.e., tremors, convulsions) are characteristic in many animals poisoned with fluoroacetate. 
Fluorocitrate administered directly into the brain was found to be 100 times more toxic than fluoro-
acetate. The accumulation of citrate in organs is characteristic of fluorocitrate poisoning; from a 
quantitative point of view the liver is less affected than the brain, heart, kidney, or spleen. 
Fluorocitrate causes extensive kidney damage, but the testes are most sensitive to sublethal doses. 
Testicular damage may be either reversible or irreversible, depending upon the dose. Several plants 
have the ability to metabolize both fluoroacetate and fluorocitrate from either inorganic or atmospheric 
fluoride. 
INTRODUCTION 
Compound 1080 (sodium monofluoroacetate) is the synthetic sodium salt of fluoroacetic acid 
(fluoroacetate) which was first identified in nature as the main toxic component in the South African 
poisonous plant, gifblaar (Dichapetalum cymosum) by Marais (1944). Its mode of action remained unknown 
for several years because investigators could not find any biochemical changes. Studies with in vitro 
test systems from rat tissues showed that it did not affect oxidative enzymes (i.e., cytochrome oxidase, 
succinoxidase, isocitric oxidase) in the tricarboxylic acid cycle (Bartlett and Barron 1947), nor did 
it have any effect on aconitase from pigeon liver (Liebecq and Peters 1949) or aconitase from pigeon 
breast and rat heart muscle (Buffa and Peters 1950).  Since fluoroacetate did not inhibit the activity 
of these and other isolated enzymes, it cannot be classified as a toxic chemical. But fluoroacetate is 
the active ingredient for controlling rodents and other vertebrate pests, so from a practical point of 
view fluoroacetate is a toxic chemical but its toxicity results from its metabolism to fluorocitric 
acid (fluorocitrate). 
For ecotoxicological reasons much of the recent research with Compound 1080 as a pesticide concerns 
environmental hazards including primary toxicity to target and nontarget animals; secondary toxicity; 
effective concentrations in baits or delivery systems; operational control methods; and analytical 
methods development (Rammell and Fleming 1978, Wade and Connolly 1980, Okuno and Meeker 1980, Hegdal 
et al. 1981, Connolly 1982, Okuno et al. 1982). Although these investigations have provided data to 
advance and aid in the operational use of 1080, studies about 1080 metabolism have been largely 
neglected. For instance, it is noteworthy that the metabolic fate of 1080 in target species such as 
coyotes (Canis latrans), prairie dogs (Cynomys spp.) and ground squirrels (Spermophilus spp.) has not 
been studied. Most of what is known about the metabolism of 1080 has been studied in albino mice and 
rats using either in vivo, but primarily in vitro test conditions. These data are then extrapolated to 
indicate what may occur in other animals. 
Metabolism of Fluoroacetate to Fluorocitrate and Mode of Action
The tricarboxylic acid (Kreb's cycle) metabolic pathway and its coupling with cytochrome oxidase 
is the major route of energy production in most aerobic animals, and disruption of this pathway at key 
enzymatic steps can lead to death. 
A simplified tricarboxylic acid cycle is depicted in Figure 1 with the enzyme aconitase shown as 
the enzyme which catalyzes the conversion of citrate to cis-aconitic acid. 
The classical explanation of 1080's toxicity is that fluorocitrate inhibits the activity of 
aconitase (Peters 1963). When aconitase is inhibited, production of energy diminishes resulting in 
cellular death and ultimately death of the whole organism. Hence 1080 is classified as a nonselective 
toxicant. But the acute LD50 (lethal dose that kills 50% of a test population) of 1080 varies consi-
derably in different animals from a low of 0.066 mg/kg, orally, in the domestic dog (Tourtellotte and 
Coon 1950) to over 500 mg/kg, intraperitoneally, in the South African clawed toad (Xenopis laevis) 
(Quin and Clark 1947). 
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Figure 1.  Diagram of the metabolism of fluoroacetate to fluorocitrate in      
the tricarboxylic acid cycle and inhibition of the enzyme aconitase by 
fluorocitrate (adapted from Egekeze and Oehme 1979). 
 
The phrase "lethal synthesis" was penned by Peters (1952) to describe the biotransformation of 
fluoroacetate to fluorocitrate. A main feature of this conversion is that synthesis and not degradation 
is involved and depends upon fluoroacetate being so stereochemically similar to acetic acid that it 
undergoes changes by enzymes in the tricarboxylic acid pathway until it is converted to fluorocitrate. 
This involves the synthesis of fluorocitrate, having six carbon atoms, from fluoroacetate which has two 
carbon atoms. 
Identification of the active toxic metabolite of fluoroacetate has not been easy. Studies of its 
isolation and properties have been described (Elliott and Kalnitsky 1950, Peters, et al. 1953a).  Small 
amounts of the toxic metabolite were formed but it was tentatively identified as fluorocitrate.  Because 
it has two asymmetric carbon atoms, four isomers are possible. Rivett (1953) and Brown and Saunders 
(1962) have synthesized fluorocitrate; and Peters et al. (1953b) found by infra-red spectra comparisons 
that the enzymatically snythesized fluorocitrate from rat kidney homogenates and synthetic fluorocitrate 
were identical, thus supporting the hypothesis that the toxicity of fluoroacetate is due to fluorocitrate.   
Dummel and Kun (1969) isolated the active isomer and identified it as L-erythrofluorocitric acid which 
inhibited aconitase activity of rat kidney mitochondria in vitro. 
Although fluorocitrate has four isomers, biochemical reactions usually do not utilize them all, 
and in recent years investigators conducting enzymatic studies with the active isomer have data which 
indicate that inhibition of aconitase is not the primary mechanism of action. Kun (1982) reviewed the 
pharmacology and toxicology of 1080 and described in great detail the molecular toxicology of          
(-)-erythrofluorocitrate, identified by Stallings et al. (1980) as 2R, 3R(-)-erythrofluorocitric acid, 
which is the active isomer of fluorocitrate. Eanes et al. (1972) found that low concentrations of this 
active isomer failed to inhibit aconitase, but it could irreversibly prevent utilization of citrate and 
cis-aconitate by liver mitochondria.  Inhibition of aconitase by fluorocitrate is reversible (Eanes and 
Kun 1974). In 1978, Kirsten et al. reported the active isomer was found on mitochondrial protein from 
rat kidney, heart, and brain which causes inhibition of citrate transport and prevents it from being 
metabolized in the tricarboxylic acid cycle. Regardless of the exact mode of action of fluorocitrate, 
the end result is that energy production is inhibited and death occurs after sufficient amounts of 
fluoroacetate have been metabolized to fluorocitrate. 
It appears that only small amounts of fluorocitrate are metabolized from fluoroacetate in animals. 
Using intact rats injected intraperitoneally with fluoroacetate-2-C14, Gal et al. 1961) conducted 
several experiments and found only small amounts of fluorocitrate. Of the total amount of radioactivity 
administered, 32% was excreted in the urine, and 3% was exhaled as C02, and about 65% of the radio-activity was retained over four days. Fluorocitrate in urine accounted for only about 3% of the 
radioactivity.  The major radioactive component in the urine did not inhibit aconitase activity. 
Another experiment by these authors provided data to suggest ..."that indeed the liver of male rat very 
poorly converts fluoroacetate to fluorocitrate in vivo."  The average radioactivity recovered as 
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fluorocitrate in the liver was 0.16% and in kidney it was 1.6%. Further evidence that fluorocitrate is 
formed in only very small amounts was reported by Schaefer and Machleidt (1971). Mice were dosed orally 
with [2- 14C] fluoroacetate, and organs such as heart, spleen, kidney, and liver were found to contain 
amino acids as the major metabolites. It was calculated that if fluorocitrate was formed, it was less 
than 2.5%. 
Acute and Chronic Toxicity of Fluorocitrate
As compared to the studies conducted on the acute and chronic oral toxicity of fluoroacetate 
(Chenoweth 1949), there are not many data for such studies with fluorocitrate. Limited data suggest 
that fluorocitrate administered orally is not as toxic as fluoroacetate. Peters and Shorthouse (1971) 
reported that 40-60 mg synthetic sodium fluorocitrate/kg intraperitoneally killed rats but that 40 mg/kg 
single oral doses of fluorocitrate..."which would be toxic by the intraperitoneal route do not kill 
most of the rats, LD20." The above doses probably do not represent the active isomer of fluorocitrate 
because in another publication it is stated that 40 mg fluorocitrate/kg is equivalent to about 4.6 mg 
"... of the active isomer of fluorocitrate..." (Peters et al. 1972a). The most extensive study on the 
oral toxicity of fluorocitrate was conducted by Peters et al. (1972a). Four-week-old male rats were 
given sublethal amounts of synthetic sodium fluorocitrate in their drinking water for seven months. 
Consumption was as much as 185 mg fluorocitrate per rat (equivalent to about 21 mg of the active isomer) 
which is several times the intraperitoneal injection lethal dose. In two of the three experiments 
animals grew and appeared normal after seven months. In the third experiment rats weighed less than 
controls, but they looked well. Organs such as the liver and kidney from fluorocitrate-fed and control 
rats examined by light and electron microscopy appeared normal and no abnormalities were found in x-ray 
examination of the bones. It was also determined that rats on fluorocitrate treatment had not become 
resistant. It was concluded that there was no toxicity in these chronically dosed rats, in contrast to 
fluoroacetate which has been described as a moderately chronic toxicant (Tucker and Crabtree 1970). 
Data from another study also indicate a low chronic toxicity of synthetic fluorocitrate (Dietrich and 
Shapiro 1956). These investigators observed no mortality and very little signs of toxicity in mice 
given daily intraperitoneal doses of 10 mg/kg twice daily (about 1.1 mg/kg of the active isomer) or 30 
mg/kg daily (about 3.3 mg/kg of the active isomer) for as long as 17 days. 
Effect of Fluorocitrate on the Central Nervous System
Many animals poisoned by fluoroacetate exhibit neurotoxic manifestations (i.e., tremors, 
convulsions), but the role of fluorocitrate in the brain remains to be defined. Gal (1972) administered 
either [2-14C] fluoroacetate or [14C] fluorocitrate intraperitoneally to rats and found a significant 
difference in the distribution of radioactivity of each chemical four hours later. Nineteen (19)% of 
the radioactivity of fluoroacetate and 52% of the radioactivity of fluorocitrate was recovered in the 
following organs: (% recovery of fluoroacetate listed first; fluorocitrate second) brain - 2.3, 0.1; 
liver - 12.0, 1.2; kidney - 2.5, 0.3; respiratory CO2 - 1.8, 0.5; and urine - 0.5, 50.0.  The high amount of fluorocitrate excreted in the urine is noteworthy and probably represents (since fluorocitrate 
is a larger molecule than fluoroacetate) the inability of fluorocitrate to be absorbed by tissue. The 
small amount of fluorocitrate in the brain (0.1%) indicates neurotoxicity can be caused by a small 
proportion of a given dose. In fact, when rats convulsed after intracerebral injection into the brain, 
the concentration of fluorocitrate was calculated to be about 25 ng/mg mitochondrial protein (1ng=1/ 
1,000,000 mg). 
Evaluating the role of fluorocitrate in the brain has been difficult because earlier experiments 
failed to demonstrate that brain tissue could metabolize fluoroacetate to fluorocitrate.  In vitro 
tests with preparations of rat and pigeon brain tissue indicated little, if any, synthesis of fluoro-
citrate from fluoroacetate (Liebecq and Peters 1949, Peters and Wakelin 1957, Peters and Shorthouse 
1966). The accumulation of citrate in tissues is one metabolic change attributed to the inhibition of 
aconitase by fluorocitrate. Buffa and Peters (1950) reported high increases of citrate levels in the 
heart, kidney, spleen, and brain of rats dosed intraperitoneally with fluoroacetate.  There was also 
an increase of citrate in blood and liver but quantitatively it was smaller. Accumulation of citrate 
after fluoroacetate poisoning also occurs in brain, heart, and kidney of pigeon and guinea pig. Again 
the increase found in the liver from both species was also quantitatively less than the other organs. 
From these data it was concluded that the citrate was produced within the cells of the respective 
organs, including brain, and this is indirect evidence that fluorocitrate can be formed from fluoro-
acetate in vivo. Direct injections of fluorocitrate into rat brain or into the lumbar subarachnoid 
space of the cat spinal cord increased the citrate content of both these central nervous system 
structures (Patel and Koenig 1971). Later, Cheng et al. (1972) found that in vitro rat brain tissue 
slices did indeed accumulate citrate after fluoroacetate treatment, indicating that metabolism of 
fluoroacetate to fluorocitrate occurred in the brain. Peters and Shorthouse (1975) reported difficulty 
in detecting fluorocitrate synthesis in brain tissue in_vitro, because of the small amount and slow 
activity of acetyl CoA synthetase in brain which converts fluoroacetate to F-acetyl-SCoA and then into 
fluorocitrate.  (cf. Fig. 1).  A long delay in the onset of neurotoxic symptoms after fluoroacetate 
administration could be accounted for by the slow metabolism to fluorocitrate. 
Fluorocitrate is a very potent toxicant when injected directly on or into nervous tissue.  
Morselli et al. (1968) found that as little as 0.56 g of the active fluorocitrate isomer was lethal to 
200 g rats when injected into various areas of the brain including nucleus medialis septi, gyrus 
dentatus, nucleus reuniens thalami, and midbrain. Convulsions were observed in 24/24 of the rats tested 
and 19/24 died. Rather surprisingly it was found that 100 g fluoroacetate injected into the brain did 
not kill any rats. From this experiment and others conducted by these investigators it was concluded 
that fluorocitrate was "at least 100 times more toxic" than fluoroacetate when injected into the brain. 
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Koenig (1969) injected 3 to 50/µg of the active fluorocitrate isomer directly into the lumbar 
subarachnoid space of cats and observed convulsions in the trunk, hindlimbs, and tail after a latent 
period of one to two hours. Microscopic examination revealed pathological conditions consisting of 
mitochondrial swelling in the neurons and an extrusion of organelles such as mitochondria and multi-
tudinous lysosomes into axons. 
Effect of Fluorocitrate on the Kidney
Pathological conditions were observed in various parts of the rat kidney after single intra-
peritoneal doses of 15 or 60 mg/kg of synthetic sodium fluorocitrate (about 1.65 or 6.6 mg/kg of the 
active isomer) (McDowell 1972a, 1973). Doses of 15 mg/kg caused gross behavioral depression in rats up 
to two hours after dosing, but after four hours they appeared normal. Rats given 60 mg/kg were mori-
bund, but none died during the two-hour observation period, at which time they were killed for tissue 
examination. Damage was dose-dependent with morphological changes in the proximal convoluted tubules 
first appearing within one to two hours after dosing. At 15 mg/kg most damage was reversible and the 
only abnormality apparent after 24 hours was high matrix densities in several mitochondria of the 
proximal convoluted tubules. The 60 mg/kg dose, however, led "...to widespread necrosis" in the 
proximal convoluted tubules. Contrary to the dose-dependent pathological changes in the proximal 
convoluted tubules, morphological changes consisting of increased vacuolation and multivesicular bodies 
in the pars recta tubules were not readily apparent with these two doses. Pathological changes seen in 
these various parts of the kidney are thought to be related to the physiological, functional, and 
metabolic differences between these segments. Fluoroacetate also causes damage to the proximal convo-
luted tubules of rat kidney but, unlike fluorocitrate, the damage was not dose-dependent (McDowell 
1972b). 
Effect of Fluoroacetate on the Testes
Although the brain may be the primary organ for producing fluorocitrate toxicity, data suggest 
that the reproductive system, particularly the testes, may be the most sensitive organ. Mazzarti et al. 
(1964, 1965) found that doses of fluoroacetate, and fluoroacetamide which is metabolized to fluoro-
acetate, inhibited sperm production and caused testicular atrophy in rats. More recently Sullivan et 
al. (1979) found elevated citrate levels and morphological damage in the testes of rats receiving 
sublethal doses of 2.2, 6.6, or 20 ppm fluoroacetate in their drinking water for seven days. Cellular 
damage consisted of depletion of spermatids and ..."formation of spermatid and spermatocyte giant 
cells." Seminiferous tubule atrophy resulted from the two higher concentrations but at the lower 
concentration regeneration of the seminiferous tubules was complete seven days after treatment, but was 
not at the two higher concentrations 21 days after treatment. No morphological changes were noted in 
the liver or kidneys. These results are interpreted to the formation of fluorocitrate which inhibits 
energy production in the testes. Severe damage to the testes, including absence of sperm, has also 
been reported in rats maintained on drinking water containing 26 ppm fluoroacetate for 126 days (Smith 
et al. 1977). 
Fluorocitrate in the Environment
Cheng et al. (1968) provided the first evidence that some plants under appropriate conditions have 
a general property to snythesize fluoroacetate and fluorocitrate. These investigators showed that 
soybean plants (Glycine max) fumigated with hydrogen fluoride or grown in nutrient media containing 
either sodium fluoride or fluoroacetate could produce both fluoroacetate or fluorocitrate.  The fluoro-
citrate produced by these plants was inhibitory to aconitase extracted from either soybean leaves or 
pig heart. 
Under environmental conditions forage crops including alfalfa (Medicago sativa) and crested wheat 
grass (Agropyron cristatum) from a pasture with a high atmospheric fluoride content accumulate both 
fluoroacetate and fluorocitrate (Lovelace et al. 1968). Both of these chemicals were identified by 
chromatographic techniques, aconitase inhibition, and infra-red spectrometric analysis. Horses grazing 
on this pasture contained more citrate in their blood than control animals and this indicates that 
fluorocitrate intoxication had occurred. 
When lettuce plants were incubated with either sodium [1-14C] acetate or sodium fluoro [1-14C] 
acetate, radioactivity was found in both fluoroacetate and fluorocitrate (Ward and Huskisson 1969). 
Single cell cultures of soya bean (Acacia georginae) and tea (Thea sinensis) grown in the presence of 
inorganic fluoride can also synthesize fluoroacetate and fluorocitrate (Peters and Shorthouse 1972). 
Small amounts of fluorocitrate, considered to be of nontoxic significance, were also detected in 
commercial samples of tea and oatmeal. 
Although the exact mode of action of the active isomer of fluorocitrate has not been conclusively 
identified, there is no doubt that it inhibits the function of the tricarboxylic acid cycle causing 
dire toxicological manifestations in animals. The central nervous system is probably the target organ 
for producing mortality seen with acute lethal doses. Pathological changes are readily apparent in the 
kidney and may contribute to the chronic toxicity of fluoroacetate. Toxic effects with sublethal doses 
of fluoroacetate, presumably mediated via fluorocitrate, are seen in the testes without causing harm 
to other organs. 
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There does not appear to be much conversion of fluorocitrate from fluoroacetate, and the 
fluorocitrate concentrations in animal tissues poisoned by Compound 1080 are most likely to be much 
lower than fluoroacetate. 
The acute and chronic toxicity of fluorocitrate appears to be much less than fluoroacetate, and 
leads to the hypothesis that the secondary toxicity hazard potential of Compound 1080 is probably due 
to the unmetabolized fluoroacetate remaining in tissue and not fluorocitrate. 
Finally, under certain environmental conditions where there are high fluoride concentrations, 
plants can synthesize both fluoroacetate and fluorocitrate. In unusual cases of suspected Compound 
1080 poisoning (i.e., livestock grazing on this type of pastureland) this source of fluoroacetate should 
be investigated. 
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